chrX-136207064-G-A
Variant summary
Our verdict is Benign. Variant got -9 ACMG points: 0P and 9B. BP4_StrongBS1_SupportingBS2
The NM_001159699.2(FHL1):c.253G>A(p.Ala85Thr) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000892 in 1,210,180 control chromosomes in the GnomAD database, with no homozygous occurrence. There are 30 hemizygotes in GnomAD. In-silico tool predicts a benign outcome for this variant. 15/19 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_001159699.2 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -9 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
FHL1 | NM_001159702.3 | c.205G>A | p.Ala69Thr | missense_variant | 4/8 | ENST00000394155.8 | NP_001153174.1 | |
FHL1 | NM_001159699.2 | c.253G>A | p.Ala85Thr | missense_variant | 3/6 | ENST00000370683.6 | NP_001153171.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
FHL1 | ENST00000394155.8 | c.205G>A | p.Ala69Thr | missense_variant | 4/8 | 5 | NM_001159702.3 | ENSP00000377710.2 | ||
FHL1 | ENST00000370683.6 | c.253G>A | p.Ala85Thr | missense_variant | 3/6 | 1 | NM_001159699.2 | ENSP00000359717.1 |
Frequencies
GnomAD3 genomes AF: 0.0000446 AC: 5AN: 112033Hom.: 0 Cov.: 24 AF XY: 0.0000292 AC XY: 1AN XY: 34219
GnomAD3 exomes AF: 0.00000546 AC: 1AN: 183118Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 67650
GnomAD4 exome AF: 0.0000938 AC: 103AN: 1098093Hom.: 0 Cov.: 31 AF XY: 0.0000798 AC XY: 29AN XY: 363487
GnomAD4 genome AF: 0.0000446 AC: 5AN: 112087Hom.: 0 Cov.: 24 AF XY: 0.0000292 AC XY: 1AN XY: 34283
ClinVar
Submissions by phenotype
X-linked myopathy with postural muscle atrophy Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Oct 13, 2022 | This sequence change replaces alanine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 69 of the FHL1 protein (p.Ala69Thr). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with FHL1-related conditions. ClinVar contains an entry for this variant (Variation ID: 537354). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Jun 06, 2019 | - - |
Cardiovascular phenotype Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Apr 11, 2022 | The p.A69T variant (also known as c.205G>A), located in coding exon 2 of the FHL1 gene, results from a G to A substitution at nucleotide position 205. The alanine at codon 69 is replaced by threonine, an amino acid with similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at